TNB-486 (also known as AZD0486)[1] "is a novel
CD19xCD3 bispecific
T-cell engager (TCE) that incorporates a unique anti-CD3 moiety designed to reduce
cytokine release syndrome by binding to
T-cells with low affinity".[2] The drug is developed for cancer by
AstraZeneca since its acquisition of TeneoTwo in 2022.[3][4][5]
TNB-486 (also known as AZD0486)[1] "is a novel
CD19xCD3 bispecific
T-cell engager (TCE) that incorporates a unique anti-CD3 moiety designed to reduce
cytokine release syndrome by binding to
T-cells with low affinity".[2] The drug is developed for cancer by
AstraZeneca since its acquisition of TeneoTwo in 2022.[3][4][5]